Skip to Main Content

Paper Details

A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer.
Invest New Drugs
12
2021
FR, Folate, Folate receptor alpha, Mirvetuximab, Mirvetuximab soravtansine, Mirvetuximab-s, Patients, TNBC, mirvetuximab, mirvetuximab-s, normal tissues, patient, patients, solid tumors, triple-negative breast cancer, triple-negative breast cancers, tumor
Author NameAffiliation
Bora LimThe University of Texas MD Anderson Cancer Center
William F SymmansThe University of Texas MD Anderson Cancer Center
  • 1 - 2

Datasets

Release 1.2